Genomic Test Predicts Outcomes In Patients With Stage I-III TNBC Treated With Neoadjuvant Chemotherapy, Study Suggests
October 31, 2024
Cancer Therapy Advisor (10/30, Ehlers) reports, “A genomic test can predict outcomes in patients with stage I-III triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy, according to a study.” The genomic “test, TNBC-DX, produced risk scores that were associated with pathologic complete response, distant disease-free survival, event-free survival, and overall survival.” The findings were published in Annals of Oncology.